Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner ...
SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the ...
March 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq ... will give an oral presentation on the Company’s clinical stage lead drug candidate GT-02287 at the AD/PD™ 2025 ...
CLEVELAND, March 04, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., will present at the Leerink ...
filed by CAR-T specialist Kyverna and private rounds for Eyconis, COUR Pharmaceuticals, Basking Biosciences, Enterprise Therapeutics, Halia Therapeutics, and NeoPhore. The underwritten offering of ...
Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...
Explore Protara Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for TARA. Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor ...
After hours: 4 March at 16:05:04 GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback